Business Wire

BAE Systems’ Active Inceptors Earn Certification on Gulfstream G600 and G500

3.12.2019 17:00:00 EET | Business Wire | Press release

Share

BAE Systems reached a critical milestone today with the certification of its active inceptors for Gulfstream’s G600 and G500 aircraft. The certifications are from the Federal Aviation Administration for the G600 aircraft and European Aviation Safety Agency for the G500 aircraft. The achievement marks the second series of certifications for BAE Systems’ active sticks in civil applications, which were first certified on Gulfstream’s G500 aircraft last year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203005196/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BAE Systems has been a world leader in active inceptor technology for more than 25 years. (Photo: BAE Systems, Inc.)

“Our active inceptors will provide pilots of these aircraft with increased situational awareness and enable enhanced handling to maintain a safe and stable flight of Gulfstream’s G500 and G600 aircraft,” said Ehtisham Siddiqui, vice president and general manager of Controls & Avionics Solutions at BAE Systems.

Unlike a passive system, active inceptors, which are part of the controls pilots use to fly an aircraft, have electronically controlled actuators that send tactile feedback to the pilot through the stick. The feedback is programmable for specific aircraft depending on customer requirements, and can warn pilots of impending structural or aerodynamic operating limits. One of the key benefits of active inceptors is the ability to link the pilot and co-pilot controls, so each can see and feel the other’s control inputs in real time.

BAE Systems has been a world leader in active inceptor technology for more than 25 years. The military version of the technology was originally developed for the Joint Strike Fighter program in the 1990s, achieving its first flight on the platform in 2000 and becoming the world’s first certified military active inceptor on the F-35 just six years later. That same core technology achieved a handful of other world firsts, which includes first flight on helicopters such as Blackhawk and Chinook. Today, the company’s active inceptors have flown on 12 different commercial and military aircraft around the world and have logged more than 200,000 flight hours.

BAE Systems is a premier provider of advanced and affordable controls, avionics, and power management systems for aircraft. From controlling the aircraft to keeping its engine running at peak performance, BAE Systems serves more than two million passengers each day. Every second of every day a plane safely takes off and lands because of its products.

For more information, visit: http://www.baesystems-ps.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

BAE Systems
Anthony DeAngelis
Office: +1 603-885-4922
Mobile: +1 603-714-3664
anthony.deangelis@baesystems.com

Amanda Desourdis
Office: +44 (0)3300 485771
Mobile: +44 (0)7990 623358
amanda.desourdis3@baesystems.com

www.baesystems.com/US
@BAESystemsInc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye